Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00009-9/abstract?utm_campaign=update-lanonc&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanonc&_hsenc=p2ANqtz-8Y-cIRsp4vSXZfOTRUqSGbEcW-NwLc2hj-7HODar5Kuv3TgK852QD_0PfWJQSD-bQI2AjR6VU4OecNSKMA_PtsHE6jiA&_hsmi=352273015&utm_content=351420884&utm_source=hs_email